Drug
Tak 861
Tak 861: highest development phase Phase 3, developed by Takeda. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-861 NCT07363720 | Phase 3 | Narcolepsy Type 1 (NT1) |
| TAK-861 NCT05687903 | Phase 2 | Narcolepsy Type 1 |
Latest
No recent events.
Follow Tak 861 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.